TACE联合瘤内碘油化疗乳剂治疗肝癌疗效观察

Observation on the results of TACE combined with lipiodol emulsion injection on hepatic carcinoma at mid and advanced stages

目的探讨肝动脉化疗栓塞(TACE)联合经皮穿剌瘤内碘油化疗乳剂(CALE)注射治疗中晚期肝癌的疗效。方法选择56例TACE术后碘油沉积不全的中晚期肝癌患者随机分为两组,26例TACE联合经皮穿剌瘤内CALE注射治疗为研究组,30例重复TACE治疗为对照组,疗程结束后查肝脏CT、彩超、AFP测定,比较两组的肿瘤缩小程度、肿瘤血供减少情况、AFP变化及随访一年生存率。结果研究组总有效率、AFP平均下降率及肿瘤血供减少率分别为76.92%,78.26%,92.3%;均高于对照组的43.33%,45.83%,63.33%(P<0.05)。研究组一年生存率为96.15%,对照组一年生存率为86.67%,两组差异无统计学意义(P>0.05)。研究组患者未发生严重并发症。结论 TACE联合经皮穿剌瘤内CALE注射治疗中晚期肝癌的疗效优于单纯的TACE治疗,且经皮穿剌注药术是安全和有效的。

Objective To evaluate the therapeutic effect of TACE combined with percutaneous CALE injection on hepatic carcinoma cases at mid and advanced stages.Methods The 56 hepatic carcinoma patients after TACE treatment were randomly divided into two groups,26 patients of TACE combined with percutaneous CALE injection were the study group,30 patients of repeated TACE were the control group.After treatment,liver CT,ultrasound,AFP were conducted.The tumor shrinkage in Two groups were compared,reduction in tumor blood supply,AFP levels and followed up one year survival rate were surveyed.Results The total effective rate,the average reduced rates of AFP,the reduction rates o blood supply to tumor in study group were 76.92%,78.26%,and 92.3%,respectively,which were significantly higher than those in control group（43.33%,45.83%,and 63.33%,respectively）（P0.05）.The one-year survival rate of the study group was 96.15%,and 86.67% in the control group.There were no significant statistical in two groups（P0.05）.Study group patients had no serious complications.Conclusion TACE combined with percutaneous CALE injection is safe and effect for treatment of hepatic carcinoma cases at mid and advanced stages.